据路透社报道， 巴西EMS和印度Torrent制药报价赛诺菲的非专利药Zentiva，估计约24亿美金。
如下是英文报道
LONDON/FRANKFURT (Reuters) – Brazilian drugs firm EMS and Indian rival Torrent Pharma have emerged as the only industry bidders for Sanofi’s generic drugs unit, battling a series of buyout funds for an asset worth as much as $2.4 billion, sources familiar with the matter told Reuters.
The two emerging market drug firms were among a group of bidders that were recently short-listed to carry out due diligence for the unit, known as Zentiva, after submitting indicative bids in January, the sources said.
Sanofi is now hoping to find a buyer by the end of the first quarter, one of the sources said, adding competition between the two drug makers and a host of buyout funds could push up the final price.
A consortium of Blackstone and Nordic Capital has also made it through the second round of the auction, the sources said, and is facing competition from three other private equity funds, namely Carlyle, BC Partners and Advent.
